[Endocrine and metabolic effects of local corticotherapy].
D015065:17-Hydroxycorticosteroids / Q000652:urine; D015068:17-Ketosteroids / Q000652:urine; D000309:Adrenal Insufficiency / Q000139:chemically induced*; D000328:Adult; D000368:Aged; D004231:Diuresis; D004357:Drug Synergism; D005260:Female; D005443:Flumethasone / Q000008:administration & dosage; D005446:Fluocinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D007018:Hypopituitarism / Q000139:chemically induced*; D007031:Hypothalamus / Q000187:drug effects*; D008010:Lichen Planus / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009318:Natriuresis; D009779:Occlusive Dressings; D010406:Penicillins / Q000627:therapeutic use; D011188:Potassium / Q000652:urine; D011565:Psoriasis / Q000188:drug therapy*; D012869:Skin Absorption; D014222:Triamcinolone Acetonide / Q000008:administration & dosage
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D010406:Penicillins; D005446:Fluocinolone Acetonide; D006919:Hydroxyzine; D014222:Triamcinolone Acetonide; D005443:Flumethasone; D011188:Potassium
Répercussions endocriniennes et métaboliques de la corticothérapie locale.